InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,425.36
(
0.53%
)
Post# of 252301
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

10nisman

Send PM Follow Ignore
Followers 24
Posts 2529
Boards Moderated 0
Alias Born 10/26/2003

10nisman

Re: jaybird249 post# 94344

Saturday, 04/17/2010 6:04:38 PM

Saturday, April 17, 2010 6:04:38 PM

Post# of 252301
<< CYCC mentioned with Merck and Pfizer: will be monster Monday:
seekingalpha.com/instablog/353981-michael-becker/63734-cyclin-dependent-cancer-confab-preview

At AACR, Cyclacel is introducing a second-generation CDK product candidate, which is currently in investigational new drug [IND]-directed development. The undisclosed molecule is a second generation oral CDK inhibitor with increased potency. Three abstracts related to both seliciclib and the second-generation compound are scheduled for presentation at AACR. >>

jaybird... Thanks for your insightful pump and dump post. Next time hit the YMB's. Thanks.

10nis
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up